An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study
Cancer Science · 2026
DOI: 10.1111/cas.70405 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Yu-Hung Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council, The Oglesby Charitable Trust, Ministry of Health and Welfare.
Abstract (Originalsprache)
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are clonal myeloid neoplasms shaped by genetic lesions and immune dysregulation, both of which contribute to disease progression and poor outcomes. Existing prognostic systems, such as IPSS‐R and IPSS‐M, do not incorporate immune alterations. We assessed the biological and clinical relevance of an immune dysfunction signature (IDS) across multi‐center MDS and CMML cohorts. IDS scores, derived from bulk transcriptomic data, were significantly associated with inferior leukemia‐free and overall survival. In multivariable analyses, IDS retained independent prognostic value alongside IPSS‐R, IPSS‐M, and bi‐allelic TP53 inactivation. Incorporation of IDS into existing models improved prognostic discrimination and time‐dependent predictive accuracy. Longitudinal analyses revealed that rising IDS scores paralleled disease progression and acute transformation, whereas declining scores were observed in remission. Biologically, IDS‐high cases demonstrated reduced cytotoxic T‐cell activity, expansion of regulatory T cells, enrichment of primitive progenitor signals, and increased expression of checkpoint pathway genes. These findings were validated across multiple independent MDS cohorts and consistently reproduced in CMML, where IDS also stratified risk and tracked disease evolution. Finally, integration with drug response signatures from the BeatAMLv2 cohort suggested potential therapeutic vulnerability of IDS‐high cases to multikinase and NF‐κB pathway inhibitors. These results establish IDS as a robust and dynamic biomarker in MDS and CMML, with applications in refined risk stratification, longitudinal disease monitoring, and guiding personalized therapeutic strategies targeting immune dysfunction. Trial Registration: #201709072RINC, #202109078RINB, #202207050RINB
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Haematology, National Taiwan University Hospital, Taipei, Taiwan.
- Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.
- Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Department of Translational Haematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Yu-Hung Wang, Wan-Hsuan Lee
Förderung
- National Science and Technology Council
- The Oglesby Charitable Trust
- Ministry of Health and Welfare
Zitieren
APA
Wang, Y. H., Gurnari, C., Visconte, V., Durmaz, A., Guarnera, L., Lee, W. H., Yao, C. Y., Jerez, A., Gurashi, K., Batta, K., Hou, H. A., Chou, W. C., Patnaik, M. S., Maciejewski, J., Wiseman, D. H., Lin, C. C., & Tien, H. F. (2026). An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study. Cancer Science. https://doi.org/10.1111/cas.70405
Vancouver
Wang YH, Gurnari C, Visconte V, Durmaz A, Guarnera L, Lee WH, et al. An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study. Cancer Science. 2026. doi:10.1111/cas.70405
BibTeX
@article{Wang2026,
author = {Wang, Yu-Hung and Gurnari, Carmelo and Visconte, Valeria and Durmaz, Arda and Guarnera, Luca and Lee, Wan-Hsuan and Yao, Chi-Yuan and Jerez, Andres and Gurashi, Kristian and Batta, Kiran and Hou, Hsin-An and Chou, Wen-Chien and Patnaik, Mrinal S and Maciejewski, Jaroslaw and Wiseman, Daniel H and Lin, Chien-Chin and Tien, Hwei-Fang},
title = {An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70405}
}
EUVIMED